Jay Lalezari

Statistics

Publications

Citations

1.9K

H-Index

Active since

2011

Affiliations

Quest Clinical Research (United States)(Current)

Johns Hopkins University

Cornell University

University of North Carolina at Chapel Hill

Virginia Mason Medical Center

Jay Lalezari is an author at Quest Clinical Research (United States) specializing in antiviral therapy, antiviral agents, and antiviral pharmacotherapy.

Publications per year

2011–2020

Publications

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

Eric Lawitz, Jay Lalezari, Tarek Hassanein et al. · The Lancet Infectious Diseases · 2013 · 328 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial

Jürgen K. Rockstroh, Mark Nelson, Christine Katlama et al. · The Lancet HIV · 2015 · 306 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1

Mark Sulkowski, Joseph J. Eron, David Wyles et al. · JAMA · 2015 · 305 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection

David Gardiner, Jay Lalezari, Eric Lawitz et al. · PLoS ONE · 2013 · 229 citations · Full text

Pharmacy, Immunology, Pharmacology +17

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

Sherene Min, Louis Sloan, Edwin DeJesus et al. · AIDS · 2011 · 216 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

1–5 of 14